.png)
.png)
CJC-1295 no DAC
Research Hub
A synthetic GHRH analogue studied for its influence on growth hormone signalling, IGF-1 activity and related endocrine pathways.
RESEARCH MATURITY
Emerging Research
● ○ ○
RESEARCH FOCUS
Growth Hormone Signalling
Pituitary Regulation
Neuroendocrine Signalling
Receptor Biology
Overview
Mechanism
Research Evidence
Studies
Application
Research Protocols
Safety
References
OVERVIEW
BPC-157 Research Overview
CJC-1295 No DAC is a synthetic peptide commonly identified as modified GRF(1–29), a compound designed to imitate the body's natural growth hormone-releasing hormone. This hormone acts as a messenger between the brain and the pituitary gland, helping regulate when growth hormone is released. CJC-1295 No DAC has attracted research interest in growth hormone signalling, hormone regulation, metabolism, and the body's natural growth-related processes.
Research has explored how compounds in this family interact with receptors that control the release of growth hormone. Growth hormone plays an important role in normal growth, tissue maintenance, and metabolism. The No DAC designation distinguishes this shorter-acting peptide from CJC-1295 with DAC, which contains a modification designed to prolong its activity in the body. Although the compounds are related, their behaviour and research findings should not be considered interchangeable.
Research into growth hormone-releasing hormones has included laboratory experiments, animal studies, and human clinical investigations of related compounds. Studies involving CJC-1295 with DAC have demonstrated changes in growth hormone and IGF-1 levels, while other investigations have helped researchers understand how the body regulates natural growth hormone release. However, these findings do not directly establish the effects of the specific compound commonly sold as CJC-1295 No DAC.
Although the underlying hormone system is well studied, direct published human clinical evidence for CJC-1295 No DAC remains very limited. Changes in growth hormone signalling do not automatically demonstrate improvements in muscle development, fat loss, physical recovery, or healthy aging. Further compound-specific research is needed to establish its biological effects, safety, and potential clinical significance.
Receptor Biology
Growth Hormone Signalling
Investigates how **growth hormone-releasing hormone receptor activation** influences pituitary growth hormone secretion and downstream IGF-1 responses in research on related GHRH analogues.
Pituitary Regulation
Neuroendocrine Signalling
Classification
Growth Hormone-Releasing Hormone (GHRH) Analogue
QUICK FACTS
29 amino acids
SEQUENCE
3,367.9 g/mol
MOLECULAR WEIGHT
MOLECULAR FORMULA
Early-stage research with developing evidence.
RESEARCH STATUS
Early-stage research with developing evidence.
RESEARCH STATUS
How BPC-157 is being investigated at the cellular and signalling level.
MECHANISM OF ACTION
EVIDENCE AT A GLANCE
CJC-1295 No DAC is commonly described as a modified growth hormone-releasing hormone fragment, but the commercial name does not always establish a precise chemical identity. Related GHRH analogues have been studied for their effects on growth hormone secretion, while published clinical findings for DAC-containing CJC-1295 concern a structurally different compound. Direct evidence for the exact No DAC formulation remains limited, making careful distinction between related peptides essential.
RESEARCH EVIDENCE
Add paragraph text.
STUDIES REVIEWED
Preclinical research across in vitro and animal models
Add paragraph text.
RESEARCH HISTORY
Research spanning several decades with continued investigation
EVIDENCE MATURITY
Emerging Research
Predominantly preclinical evidence with limited human research
EVIDENCE CONTEXT
Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.
Proposed Mechanism
CJC-1295 No DAC is a commercial name generally used for a modified fragment of growth hormone-releasing hormone (GHRH). GHRH is a natural hormone that signals the pituitary gland to release growth hormone.
The proposed mechanism involves binding to GHRH receptors on pituitary cells and activating internal signaling that promotes growth hormone release. The No DAC designation indicates that the peptide lacks the albumin-binding modification associated with the longer-acting compound formally described in published studies as CJC-1295.
This distinction matters because the two forms have different molecular structures and expected durations of activity. Research findings for DAC-containing CJC-1295 should not automatically be attributed to a No DAC product, whose exact sequence and identity require confirmation.
Proposed Visual
PROPOSE RESEARCH PATHWAY
Compound
BIOLOGICAL TARGET
SIGNALLING RESPONSE
RESEARCH OUTCOME
CJC-1295 no DAC
A synthetic GHRH analogue studied for its influence on growth hormone signalling, IGF-1 activity and related endocrine pathways.
CJC-1295 No DAC is a synthetic peptide commonly identified as modified GRF(1–29), a compound designed to imitate the body's natural growth hormone-releasing hormone. This hormone acts as a messenger between the brain and the pituitary gland, helping regulate when growth hormone is released. CJC-1295 No DAC has attracted research interest in growth hormone signalling, hormone regulation, metabolism, and the body's natural growth-related processes.
Research has explored how compounds in this family interact with receptors that control the release of growth hormone. Growth hormone plays an important role in normal growth, tissue maintenance, and metabolism. The No DAC designation distinguishes this shorter-acting peptide from CJC-1295 with DAC, which contains a modification designed to prolong its activity in the body. Although the compounds are related, their behaviour and research findings should not be considered interchangeable.
Research into growth hormone-releasing hormones has included laboratory experiments, animal studies, and human clinical investigations of related compounds. Studies involving CJC-1295 with DAC have demonstrated changes in growth hormone and IGF-1 levels, while other investigations have helped researchers understand how the body regulates natural growth hormone release. However, these findings do not directly establish the effects of the specific compound commonly sold as CJC-1295 No DAC.
Although the underlying hormone system is well studied, direct published human clinical evidence for CJC-1295 No DAC remains very limited. Changes in growth hormone signalling do not automatically demonstrate improvements in muscle development, fat loss, physical recovery, or healthy aging. Further compound-specific research is needed to establish its biological effects, safety, and potential clinical significance.